Detailed description page of THPdb

This page displays user query in tabular form.

Th1116 details

Primary information
ID 1537
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Interleukin-1 beta
Information of corresponding available drug in the market
Brand Name ILARISÂ
Company Novartis Pharmaceuticals
Brand Discription Canakinumab is a recombinant, human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447-(or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). The biological activity of canakinumab is measured by comparing its inhibition of IL-1Î²-dependent expression of the reporter gene luciferase to that of a canakinumab internal reference standard, using a stably transfected cell line.
Prescribed for Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA)
Chemical Name N.A.
Formulation Reconstitution with 1 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug. The reconstituted canakinumab is a 150 mg/mL solution essentially free of particulates, clear to slightly opalescent, and is colorless or may have a slightly brownish-yellow tint. A volume of up to 1 mL can be withdrawn for delivery of 150 mg/mL canakinumab for subcutaneous administration. Each reconstituted vial contains 180 mg canakinumab, sucrose, L-histidine, L-histidine HCL monohydrate, polysorbate 80 and Sterile Water for Injection. No preservatives are present.
Physcial Appearance 180 mg of canakinumab as a white, preservative-free, lyophilized powder
Route of Administration Subcutaneous
Recommended Dosage Cryopyrin-Associated Periodic Syndromes (CAPS): The recommended dose of ILARIS is 150 mg for CAPS patients with body weight greater than 40 kg. For CAPS patients with body weight greater than or equal to 15 kg and less than or equal to 40 kg, the recommended dose is 2 mg/kg. For children 15 to 40 kg with an inadequate response, the dose can be increased to 3 mg/kg. Systemic Juvenile Idiopathic Arthritis (SJIA): The recommended dose of ILARIS for SJIA patients with a body weight greater than or equal to 7.5 kg is 4mg/kg (with a maximum of 300 mg) administered every four weeks via subcutaneous injection.
Contraindication Confirmed hypersensitivity to the active substance or to any of the excipients.
Side Effects ILARIS has been associated with an increased risk of serious infections, Immunosuppression, Hypersensitivity , Live vaccines should not be given concurrently with ILARIS.
Useful Link https://www.pharma.us.novartis.com/product/pi/pdf/ilaris.pdf http://www.rxlist.com/ilaris-drug/warnings-precautions.htm
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1538
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1539
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1540
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1541
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1542
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1543
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1544
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1545
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1546
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID 1547
ThPP ID Th1116
Therapeutic Peptide/Protein Name Canakinumab
Sequence H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification IIIb
Molecular Weight 145200 (deglycosylated)
Chemical Formula C6452H9958N1722O2010S42
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 26 days
Description Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism The metabolism of canakinumab is not yet determined.
Absorption The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution 6.01 L [typical CAPS patient weighing 70 kg]
Clearance 0.174 L/day [typical CAPS patient weighing 70 kg]
Categories Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 23553601, 23319019, 19494217, 19169963
3-D Structure Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1537
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Interleukin-1 beta
Information of corresponding available drug in the market
Brand Name	ILARISÂ
Company	Novartis Pharmaceuticals
Brand Discription	Canakinumab is a recombinant, human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447-(or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). The biological activity of canakinumab is measured by comparing its inhibition of IL-1Î²-dependent expression of the reporter gene luciferase to that of a canakinumab internal reference standard, using a stably transfected cell line.
Prescribed for	Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA)
Chemical Name	N.A.
Formulation	Reconstitution with 1 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug. The reconstituted canakinumab is a 150 mg/mL solution essentially free of particulates, clear to slightly opalescent, and is colorless or may have a slightly brownish-yellow tint. A volume of up to 1 mL can be withdrawn for delivery of 150 mg/mL canakinumab for subcutaneous administration. Each reconstituted vial contains 180 mg canakinumab, sucrose, L-histidine, L-histidine HCL monohydrate, polysorbate 80 and Sterile Water for Injection. No preservatives are present.
Physcial Appearance	180 mg of canakinumab as a white, preservative-free, lyophilized powder
Route of Administration	Subcutaneous
Recommended Dosage	Cryopyrin-Associated Periodic Syndromes (CAPS): The recommended dose of ILARIS is 150 mg for CAPS patients with body weight greater than 40 kg. For CAPS patients with body weight greater than or equal to 15 kg and less than or equal to 40 kg, the recommended dose is 2 mg/kg. For children 15 to 40 kg with an inadequate response, the dose can be increased to 3 mg/kg. Systemic Juvenile Idiopathic Arthritis (SJIA): The recommended dose of ILARIS for SJIA patients with a body weight greater than or equal to 7.5 kg is 4mg/kg (with a maximum of 300 mg) administered every four weeks via subcutaneous injection.
Contraindication	Confirmed hypersensitivity to the active substance or to any of the excipients.
Side Effects	ILARIS has been associated with an increased risk of serious infections, Immunosuppression, Hypersensitivity , Live vaccines should not be given concurrently with ILARIS.
Useful Link	https://www.pharma.us.novartis.com/product/pi/pdf/ilaris.pdf http://www.rxlist.com/ilaris-drug/warnings-precautions.htm
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1538
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1539
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1540
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1541
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1542
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1543
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1544
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1545
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1546
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Primary information
ID	1547
ThPP ID	Th1116
Therapeutic Peptide/Protein Name	Canakinumab
Sequence	H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217 view full sequnce in fasta
Functional Classification	IIIb
Molecular Weight	145200 (deglycosylated)
Chemical Formula	C6452H9958N1722O2010S42
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	26 days
Description	Canakinumab is a recombinant (from murine Sp2/0-Ag14 cell line), human anti-human-IL-1Î² monoclonal antibody that belongs to the IgG1/Îº isotype subclass. It comprises of two 447- or 448-residue heavy chains and two 214-residue light chains. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at N298. It binds to human IL-1Î², thereby neutralizing its inflammatory activity by preventing its interaction with IL-1 receptors. However it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). It is marketed under the brand name Ilaris.
Indication/Disease	For the treatment of patients aged 4 years and older, to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS). It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in patients pf age 2 years and older . It can be effectively afe and effective, offerin and is therefore considered a significantly better option cted daily and which is often poorly tolerated by the young patients
Pharmacodynamics	Novartis AG has developed canakinumab as a subcutaneous injection and fully human mAb that neutralizes the bioactivity of human IL-1beta, which is involved in several inflammatory disorders. Canakinumab has promising clinical safety and pharmacokinetic properties, and demonstrated potential for the treatment of cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and possibly for other complex inflammatory diseases, such as rheumatoid arthritis, COPD disease and ocular diseases.
Mechanism of Action	In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1Î²) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1Î², and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1Î² activation. Canakinumab is a human monoclonal anti-human IL-1Î² antibody of the IgG1/Îº isotype. Canakinumab binds to human IL-1Î² and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1Î±Â± or IL-1 receptor antagonist (IL-1ra).
Toxicity	The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
Metabolism	The metabolism of canakinumab is not yet determined.
Absorption	The absolute bioavailability of subcutaneous canakinumab is estimated to be 70%.
Volume of Distribution	6.01 L [typical CAPS patient weighing 70 kg]
Clearance	0.174 L/day [typical CAPS patient weighing 70 kg]
Categories	Anti-Inflammatory Agents and Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	23553601, 23319019, 19494217, 19169963
3-D Structure	Th1116 A chain or (Download), Th1116 B chain (View) or (Download)

Updated version of this database is available at ThpDB2

Detailed description page of THPdb